This site contains promotional information intended only for healthcare professionals resident in Great Britain

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Maternal ImmunisationMaternal
ImmunisationMaternal Immunisation HomepageSafety ProfileDosingOlder AdultsOlder AdultsOlder Adults HomepageSafety ProfileDosingPreparationUseful ResourcesUseful
ResourcesVideosMaterials

The content of this website has been produced in line with the ABRYSVO®▼(Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain only. ABRYSVO▼ Prescribing Information for Great Britain click here. ABRYSVO▼ Prescribing Information for Northern Ireland click here.

A new RSV National Immunisation Programme for 20241
ABRYSVO is indicated for: 2
  • Passive protection against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age following maternal immunisation during pregnancy.2 For maternal immunisation a dose of 0.5 mL should be administered between weeks 28 and 36 of gestation of pregnancy Great Britain(GB) and 24 and 36  weeks of gestation of pregnancy Northern Ireland (NI).2,3
  • Active immunisation of individuals 60 years of age and older for the prevention of LRTD caused by RSV.2

The use of this vaccine should be in accordance with official recommendations.2 

 
Below, are the decisions made by UKHSA and NHS across the devolved nations on how the RSV programme will be delivered.
 England
VISIT: GOV.UK Page
Loading Scotland VISIT: Adult NHS Inform Loading VISIT: Pregnancy NHS InformLoading Wales
VISIT: Public Health Wales 
Loading Northern IrelandVISIT: Department of Health NI Loading
VISIT: Green Book Chapter on RSV
Loading

Any further questions or information regarding the programme, speak to your UKHSA immunisation lead.
Maternal Immunisation with ABRYSVO

Learn more about maternal immunisation with ABRYSVO.

 Learn moreLoading
ABRYSVO in Older Adults


Find out more about the use of ABRYSVO in older adults.

 Learn moreLoading
Preparation of ABRYSVO

 

Watch a video on how to prepare ABRYSVO for administration. Learn moreLoading
Useful Resources

 

Explore the ABRYSVO resources section for useful videos and materials. VideosLoading Materials Learn more about RSV & ABRYSVO with 5-minute eModules

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

 eModule 1: Understand RSV disease and the at-risk populations Loading eModule 2: What is ABRYSVO?
  1. United Kingdom Health Security Agency (UKHSA). Respiratory syncytial virus (RSV) vaccination programme. Available at: https://www.gov.uk/government/collections/respiratory-syncytial-virus-rsv-vaccination-programme. Accessed July 2024.
  2. ABRYSVO (Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Summary of Product Characteristics for Great Britain. Available at: https://www.medicines.org.uk/emc/product/15309.
  3. ABRYSVO (Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Summary of Product Characteristics for Northern Ireland. Available at: https://www.emcmedicines.com/en-gb/northernireland/medicine?id=a888fc4d-f2b3-4d38-90ed-9f189ab12911&type=smpc.
PP-A1G-GBR-0146. July 2024.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​